(Q39432147)

11 September 2017

title

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth (English)

1 reference

11 September 2017

1 reference

Susan L Cohn

9

0 references

author name string

Nisha C Kakodkar

1

1 reference

11 September 2017

Radhika R Peddinti

2

1 reference

11 September 2017

Yufeng Tian

3

1 reference

11 September 2017

Lisa J Guerrero

4

1 reference

11 September 2017

Alexandre Chlenski

5

1 reference

11 September 2017

Qiwei Yang

6

1 reference

11 September 2017

Helen R Salwen

7

1 reference

11 September 2017

Michael L Maitland

8

1 reference

11 September 2017

publication date

6 December 2011

1 reference

11 September 2017

published in

Pediatric Blood & Cancer

1 reference

11 September 2017

volume

59

1 reference

11 September 2017

issue

4

1 reference

11 September 2017

page(s)

642-647

1 reference

11 September 2017

1 reference

Neuroblastoma: biology, prognosis, and treatment

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

21 January 2018

1 reference

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

The regulation of angiogenesis in neuroblastoma

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma

21 January 2018

1 reference

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.

21 January 2018

1 reference

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors

21 January 2018

1 reference

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

21 January 2018

1 reference

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors

21 January 2018

1 reference

Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-a

21 January 2018

1 reference

Signal transduction via the MAP kinases: proceed at your own RSK.

21 January 2018

1 reference

Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling

21 January 2018

1 reference

Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.24004

1 reference

11 September 2017

1 reference